InvestorBrandNetwork (IBN) Content Platform

The SPAC process continues to be an effective way to take a developing company public while avoiding the complications and costs associated with a traditional IPO. This is especially true today due to investor uncertainties created by a rapidly shifting equities market. SPACs continue to represent an important opportunity for those who know how best to utilize them. The SPAC Conference delivers cutting-edge insights into how to use this opportunity to meet your investment liquidity or corporate growth objectives.

To find out more about the event, visit https://ibn.fm/L0Vbe

To view the full article, visit https://ibn.fm/MQo82

About DealFlow Events

When it comes to the business of finance, the tagline “A DealFlow Event” is widely recognized as a symbol of quality. DealFlow Events has produced over 200 conferences, seminars, and webcasts on a variety of financial topics. These events are the signature programs in their respective markets, offering high-quality content and professional networking opportunities. For more information, visit www.DealFlowEvents.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

DealFlow Events, host of the upcoming Reg A Conference, announced that it has selected IBN (InvestorBrandNetwork), a multifaceted communications organization, as the official media partner for the event. The conference is slated for June 30, 2023, and will be held in Rye, New York. According to the announcement, the one-day event will be this year’s largest gathering of dealmakers and companies interested in Regulation A capital-raising strategies, which require knowledge of specific reporting requirements and disclosure rules in order to execute correctly. The Reg A Conference provides an ideal opportunity for participants to gain invaluable knowledge about Reg A. The event agenda features sessions hosted by some 20 industry experts. Conference attendees include representatives of public and private companies looking to raise capital as well as investment professionals such as Reg A investors, investment bankers, fund managers, hedge funds and private equity experts, deal advisors and marketing consultants.

Through its 60-plus brands, IBN has garnered impressive expertise in connecting companies to the investment community. IBN will leverage its extensive network to increase awareness of the conference. “Having hosted hundreds of conferences, seminars and webcasts on a variety of financial topics, DealFlow Events has an incredible track record and strong base of returning attendees,” said IBN communications director Jonathan Keim in the press release. “Their events are well-known for providing high-quality educational and networking content. We appreciate the opportunity to collaborate closely with DealFlow Events while driving greater visibility for the Reg A process, invited speakers, participating companies and conference as a whole.”

To learn more about the conference, visit https://ibn.fm/bH5eC

To view the full press release, visit https://ibn.fm/9Q5d2

About DealFlow

DealFlow began in 2003 by providing independent research for finance professionals at DealFlow Media. The company has been the publisher of popular newsletters, investment databases and research reports. As history has proven, DealFlow has been first to uncover many important investment and business trends, pairing its information products with highly regarded events. Today the company is focused on bringing events to people looking for exclusive networking, education and business-development opportunities. To learn more about the company, please visit www.DealFlowEvents.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER), the nation’s leading independent alkaline water company and the Clean Beverage(R) company, has expanded the distribution of its Alkaline88(R) 1-liter six-pack. According to the announcement, after the most recent expansion, including the addition of approximately 1,250 retail locations of a well-recognized grocery chain, the product is available throughout the southeastern United States. The company noted that its Alkaline88 1-gallon offering is already a “fixture in tens of thousands of grocery locations” and ranks as the country’s best-selling, gallon-sized enhanced water product; WTER is now targeting the grocery channel’s best-selling size format in the 1-Liter, six-pack category. “Adding the Alkaline88 1-Liter six-pack to 1,250 additional supermarket locations in the Southeast now makes this fantastic SKU available to millions of shoppers in approximately 4,000 stores throughout the region,” said The Alkaline Water Company CEO and president Frank Chessman in the press release. “In addition to boasting the best-selling gallon product in the category by a significant margin, we’re now leveraging the best-selling size format to expand Alkaline88’s presence in the grocery channel and push for even more market share for the brand.”

To view the full press release, visit https://ibn.fm/X0Ccv

About The Alkaline Water Company

The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with ecofriendly aluminum packaging options. With its innovative, state-of-the-art, proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH alkaline drinking water with trace minerals and electrolytes and boasts the company’s trademarked Clean Beverage label. To learn more about the company, please visit www.Alkaline88.com and www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

IBN (“InvestorBrandNetwork”), a multifaceted communications organization engaged in connecting companies to the investment community through 60+ brands, today announced its designation as the official media partner for The SPAC Conference 2023. Hosted by DealFlow Financial Products, Inc. (“DealFlow Events”), the conference is slated to take place at the Westchester Country Club in Rye, New York, on June 28-29. The largest forum for networking and discussion of Special Purpose Acquisition Companies (“SPACs”) and alternative IPO techniques, the event will feature 35+ key speakers and draw leading brokerages, law firms, seasoned institutional investors, investment bankers, fund managers, hedge funds and SPAC investors, well-connected investor relations professionals, private equity representatives, SPAC targets, deal advisors, and a host of other professionals. As the media sponsor, IBN will leverage its extensive corporate communications solutions to heighten the visibility of the conference via an array of influential digital channels to an audience of management teams, investors, financial journalists, and the broader public. “Our SPAC Conference series is a key part of our overall strategy to generate awareness of the various structures available for financial transactions. We are very pleased to continue collaborating with IBN as they continue to raise the visibility of our events throughout the online investment community,” said Steven Dresner, CEO of DealFlow Events. “We appreciate their highly professional and energetic team.”

To view the full press release, visit https://ibn.fm/5Wsz3

About IBN

IBN consists of financial brands introduced to the investment public over the course of 17+ years. IBN has amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand this branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve an increasingly diversified list of clients.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTC: PLTXF), the digital face of the plant-based community operating a one-stop shop for plant-based products, is teaming up with the Macromia Group, a restaurant developer specializing in building high-end dining and retail locations from concept to creation. According to the announcement, PlantX Life is engaging Macromia to assist with completing the construction and then the operation of its XMarket Vegan Food Hall, located in Chicago. The innovative food hall will include a central bar with vegan bar food and vegan wine pairings along with a bodega-style grocery store with a cheese monger provided by Good Planet as well as six unique concepts including a coffee roaster featuring PlantX’s own Portfolio Coffee. The company anticipates opening the site, which will be Chicago’s largest vegan food hall, by Labor Day weekend. “Chicago has emerged as one of the largest vegan and health-conscious communities in North America, making it an ideal location to introduce our all-in-one vegan food hall concept,” said PlantX Life CEO Lorne Rapkin in the press release. “In collaboration with Macromia, the master in developing premium concepts that have garnered both a loyal following and critical acclaim, we are planning an amazing culinary experience that will set the standard for food halls for vegans and non-vegans alike. We’re excited for our opening, which is only two months away.”

To view the full press release, visit https://ibn.fm/IS5fl

About PlantX Life Inc.

PlantX is committed to being the digital face of the plant-based community as well as the one-stop shop for plant-based products. With its fast-growing category verticals, the company offers customers across North America more than 5,000 plant-based products. PlantX also has other brands in the PlantX portfolio, including a juice brand, a coffee company, a plant shop and brick-and-mortar grocery stores. PlantX uses its digital platform to build a community of like-minded consumers and, most importantly, to provide education. PlantX’s digital presence eliminates entry barriers for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life. For more information about this company, please visit www.PlantX.com and www.PlantX.ca.

NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Golden Triangle Ventures (OTC: GTVH), a multifaceted financial news and publishing company for private and public entities, has completed its acquisition of Le Pragma LLC and has fully acquired all assets and intellectual property of the company. Le Pragma is a full retail line of high-end, all-natural health, wellness and beauty products. Le Pragma was designed to have a universal appeal as a global luxury health and wellness brand, featuring the therapeutic benefits of novel cannabinoids and with a strategic vision of becoming the “CBD line of the future.” The company’s cutting-edge formulations and commitment to precise science differentiates its products; its CBD product line features tinctures, wellness pills, pain cream, lip balm and a five-step CBD skincare system. Golden Triangle plans to support the company’s past research and well-established position within the industrial hemp industry by expanding the product line into both nootropics and pharmaceutical-grade CBD products that will provide targeted benefits for specific ailments.

GTVH anticipates updating Le Pragma’s website and working to expand its sales distribution channels by contacting retail stores that carry CBD products to assess distribution potential. The company is also working with social media influencers and bloggers to represent Le Pragma and will be implementing digital advertisements, phone calls, street teams, email campaigns, SEO, online distribution partners and more to increase the product line’s exposure and sales. In addition, the announcement noted that Sonder Fulfillment, a wholly owned subsidiary of GTV, plans to leverage its global relationships and strategic partnerships to lay the groundwork for entry into international markets. “Management has a strong plan in place to rapidly develop retail sales of the product line, which will greatly assist the completion of its previously announced spin-offs,” Golden Triangle Ventures states in the press release. “The company looks forward to formally disclosing other exciting accomplishments following this initial achievement.”

To view the full press release, visit https://ibn.fm/vlSMj

About Golden Triangle Ventures Inc.

Golden Triangle Ventures is a multifaceted consulting company, which operates as the parent business pursuing ventures in the health, entertainment and technology sectors along with others that provide synergistic value to these three core divisions. The company aims to purchase, acquire and/or joint venture with established entities within these areas of business. The goods and services represented are driven by innovators that have passion and commitment in these marketplaces. The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent the three sectors the company aims to do business in. Golden Triangle Ventures is highly focused on acquiring a well-diversified portfolio of companies under one umbrella, which are all managed and owned by the company. An amazing team of professionals support each division and continue to help Golden Triangle Ventures grow daily. Operating as a publicly traded company gives the ability to provide the support needed to help each subsidiary grow into the businesses management believes they can and will become. For more information about the company, please visit www.GoldenTriangleInc.com.  

NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://ibn.fm/GTVH

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

EverGen (TSX.V: EVGN) (OTCQX: EVGIF) has issued a construction update for its Fraser Valley Biogas project and reported the successful drawdown of $15 million under the first tranche of the previously announced $31 million syndicated senior term loan from Roynat Capital and Export Development Canada (“EDC”). This provides EverGen with financial certainty to fund the Fraser Valley Biogas core RNG expansion project currently under construction. “This marks the final stage of construction of our core RNG expansion project at Fraser Valley Biogas, which will be completed in Q3 2023,” said Chase Edgelow, CEO of EverGen. “We prudently structure the financing behind each of our projects to allow for flexibility and to maximize returns for our shareholders.”

To view the full press release, visit https://ibn.fm/nJS4m

About EverGen Infrastructure Corp.

EverGen, Canada’s renewable natural gas (“RNG”) infrastructure platform, is combating climate change and helping communities contribute to a sustainable future. Headquartered on the West Coast of Canada, EverGen is an established independent renewable energy producer, which acquires, develops, builds, owns and operates a portfolio of renewable natural gas, waste to energy and related infrastructure projects. EverGen is focused on Canada, with continued growth expected across other regions in North America and beyond. For more information, visit the company’s website at www.EverGenInfra.com.

NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is releasing its 2023 fiscal year report. Highlights of the report include positive results reported in the company’s phase 3 open label study of fasedienol (“PH94B”) in social anxiety disorder (“SAD”) as well as the positive feedback received from the U.S. Food and Drug Administration (“FDA”) regarding the use of the Liebowitz Social Anxiety Scale (“LSAS”) as the primary efficacy endpoint in phase 3 studies planned for fasedienol. In addition, Vistagen’s successful itruvone (“PH10”) U.S. phase 1 study supports previous successful phase 1 studies and a positive phase 2A study in major depressive disorder (“MDD”) as well as the anticipated next-step U.S. phase 2B development. The report noted that the company’s clinical-stage pipeline has grown to six differentiated product candidates and that the company is actively working to pursue key global and regional strategic development and commercialization partnerships designed to accelerate milestones across the CNS pipeline. Financial highlights included a $9 million increase in research and development, with R&D expense reaching $44 million for the year, up from $35.4 million in the previous year; a $1.2 million increase in general and administrative expenses, which totaled $14.7 million for the 2023 fiscal year; a net loss attributable to common stockholders for the year of $59.2 million; and cash and cash equivalents of approximately $16.6 million.

The company noted that it currently has 7,872,479 shares of common stock outstanding as a result of its recent 1-for-30 reverse stock split, which enabled Vistagen to regain full compliance with NASDAQ listing requirements. “We continue to make significant progress across our CNS pipeline, which now includes six innovative clinical-stage product candidates, each with a differentiated mechanism of action, a favorable safety profile and substantial potential to improve millions of lives affected by anxiety, depression, hot flashes due to menopause and several other large market CNS disorders without therapeutic options that adequately satisfy patient needs,” said Vistagen CEO Shawn Singh in the press release. “Our deep understanding of the science and therapeutic potential underlying each of our product candidates provides a firm foundation for our confidence in our future. Given the collective body of positive safety and efficacy studies supporting our clinical-stage pipeline, now is the opportune time to amplify our efforts with multiple global and regional strategic development and commercialization partnerships across our portfolio to accelerate achieving key clinical and regulatory milestones within each program.”

To view the full press release, visit https://ibn.fm/oQN8X

About Vistagen Therapeutics Inc.

Vistagen Therapeutics is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company is advancing therapeutics with the potential to be faster acting and with fewer side effects and safety concerns than treatments that are currently available for treatment of anxiety, depression and multiple CNS disorders. Vistagen’s pipeline includes six clinical-stage product candidates, including fasedienol (“PH94B”), itruvone (“PH10”), PH15, PH80 and PH284, each an investigational agent belonging to a new class of drugs known as pherines, as well as AV-101, which is an oral antagonist of the N-methyl-D-aspartate receptor (NMDAR). Pherines, which are administered as low-dose nasal sprays, are designed with a novel rapid-onset mechanism of action that activates chemosensory neurons in the nasal cavity and can beneficially impact key neural circuits in the brain without systemic uptake or direct activity on CNS neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety, depression and several other CNS disorders. For more information about the company, please visit www.Vistagen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN  

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

• Starco Brands, Inc.’s Whipshots has rapidly emerged as one of the fastest-growing spirits in history
• The alcoholic beverage, launched in collaboration with Cardi B and recently highlighted by Forbes Magazine, has just launched its new summer campaign, entitled “Summer of Whipshots”
• Featuring Cardi B in a 30-second video and showcasing the product used in a number of summer drinks, the campaign has already racked up millions of views and ‘likes’ online

Starco Brands (OTCQB: STCB) has long made it its unwavering mission to create “consumer products with behavior-changing technologies that spark excitement in the everyday.” A modern-day “invention factory” focused around inventing or acquiring novel products and subsequently advancing them using behavior-changing technologies, has recently hit upon yet another breakthrough product offering through Whipshots®, a unique vodka-infused line of whipped cream products used in cocktails, currently making waves throughout the global beverage market.

Figures from Statista have recently forecast the global market size of the alcoholic beverage market to surpass $2.2 trillion by 2025, driven by increasingly discerning customer tastes and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to STCB are available in the company’s newsroom at https://ibn.fm/STCB

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

Ideanomics (NASDAQ: IDEX), a global company with the mission to accelerate the adoption of electric vehicles, and its subsidiary, Solectrac, is launching an electric tractor rental program. The first electric tractor manufacturer to offer its zero-emission products through direct sales and a certified national dealer network, Solectrac is committed to identifying new solutions for electric mobility. This innovative electric tractor rental program will allow even more customers to experience the benefits of zero-emissions operations. The program features Solectrac’s 4WD e25G compact electric tractor, a quiet and powerful zero-emission tractor that eliminates the noise and pollution often associated with traditional diesel tractors. According to the announcement, the new rental program will benefit Solectrac’s dealer network in more than 70 locations across the United States by offering prospective electric tractor customers an opportunity to experience firsthand the operational and health benefits of Solectrac’s market-leading technology. “We want to offer our customers a way to familiarize themselves with our new technology without necessarily having to make a large financial decision of purchasing a tractor,” said Solectrac CEO Mani Iyer in the press release. “We also know that smaller operations may only need a tractor occasionally. We want to facilitate getting our zero-emission equipment into as many operations as possible. Electric tractors not only eliminate on-site emissions, but they provide a healthier work environment for operators.” 

To view the full press release, visit https://ibn.fm/obNLq

About Ideanomics Inc.

Ideanomics is a global group with a simple mission: to accelerate the commercial adoption of electric vehicles. By bringing together vehicles, charging and financing solutions under one roof, Ideanomics is the one-stop partner needed to simplify the transition to, and operation of, any EV fleet. For more information about the company, please visit www.Ideanomics.com.

NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has received Fast Track Designation (“FTD”) from the U.S. Food and Drug Administration (“FDA”) for its lead drug candidate, REQORSA(R) Immunogene Therapy; the designation applies when used in combination with Genentech Inc.’s Tecentriq(R) to treat patients with extensive-stage small cell lung cancer (“ES-SCLC”) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. According to the announcement, this is the third FTD granted to Genprex’s REQORSA. The company noted that it anticipates enrolling the first patient in its Acclaim-3 clinical trial, which is a phase 1/2 dose escalation and clinical response study of maintenance therapy evaluating REQORSA in combination with Tecentriq for this patient population. “We are very pleased to receive a third Fast Track Designation from the FDA for REQORSA, this time for patients with ES-SCLC in combination with the checkpoint inhibitor Tecentriq,” said Genprex president, chair and CEO Rodney Varner in the press release. “This is another exciting achievement in our REQORSA development program, which further validates REQORSA’s potential not only in NSCLC but also in SCLC. We look forward to accelerating the clinical development of REQORSA, and potentially providing a new treatment option for patients with SCLC.”

To view the full press release, visit https://ibn.fm/0xQPB

About Genprex Inc. 

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, which currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its proprietary, nonviral ONCOPREX(R) Nanoparticle Delivery System, which encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is then administered intravenously, where it is then taken up by tumor cells that express tumor suppressor proteins that are deficient in the tumor. The company’s lead product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (“NSCLC”) and small cell lung cancer (“SCLC”). Both NSCLC clinical programs received a fast-track designation from the Food and Drug Administration. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (“AAV”) vector to deliver Pdx1 (“Pdx1”) and MafA (“MafA”) genes to the pancreas. In models of type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-003 for type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. For more information, please visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting on its audited financial results for the fiscal year ended March 31, 2023. Highlights of the report include total cash of C$16.6 million with net loss of C$13.7 million for the quarter, compared to a net loss of C$18.1 million in the same period last year, and net loss of C$47.5 million for the fiscal year, compared to a net loss of C$67.6 million in the same period last year. Operating expenses decreased, coming in at C$51.5 million for the year compared to C$63.8 million in the previous year. Corporate highlights included promising interim safety and pharmacodynamic data released from the company’s ongoing phase 1/2a study in major depressive disorder (“MDD”); the company’s accelerated clinical development path for CYB004; the initiation of first in-human dosing of CYB004 in its phase 1 trial evaluating IV DMT and CYB004; and the launching of EMBARK Open Access, a free online foundational training course offering psychedelic facilitation training.

“During the past year, we have made significant progress advancing our two lead clinical programs, CYB003 and CYB004,” said Cybin CEO Doug Drysdale in the press release. “We expect to share topline results later this year, with the potential to submit CYB003 phase 1/2a data to the FDA in the fourth calendar quarter of 2023 for an end of phase 2 meeting. We are also encouraged by the recently announced draft FDA guidelines signaling the FDA’s commitment to a clear regulatory pathway for psychedelic drug development. Importantly, these guidelines also help remove regulatory uncertainty for investors and clinical trial sponsors. With these catalysts in our sights, we believe that we are moving ever closer to our goal of developing treatment options, as demonstrated in our phase 1 and phase 2 studies to date.”

To view the full press release, visit https://ibn.fm/ClULk

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder; the company also has a research pipeline of investigational psychedelic-based compounds. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

The Sustainable Green Team (OTCQX: SGTM), a provider of environmentally conscious solutions in the arbor care, disposal and recycling industries, today announced that it has hired First Level Capital LLC, a full-service advisory and investor relations firm. According to the update, First Level Capital will provide strategic business advisory and investor relations services for SGTM’s 2023 and 2024 corporate initiative roadmap, including its goal of a proposed uplisting to the Nasdaq exchange. “After meeting with the First Level Capital team at our Nasdaq interview and discussing our corporate initiatives for the next several months, we felt the timing was right to retain the firm in order to advance our roadmap as articulated in SGTM’s Form 10 filed earlier this month,” said SGTM CEO Tony Raynor. “As we hope to complete our goal of becoming a fully reporting company, we look forward to working with First Level Capital and their team while leveraging their expertise to achieve our goals.”

To view the full press release, visit https://ibn.fm/0NRYs

About Sustainable Green Team Ltd.

The Sustainable Green Team is a wholesale manufacturer and national supplier of wood-based mulch, lumber products and soil, including soil amendment products HumiSoil(R) and XLR8(R). The company sells directly to mass merchandisers, home centers, hardware stores, nurseries, garden centers, convenience stores, food stores, and wholesale distributors. The company’s primary corporate objective is to provide a solution for the treatment and handling of tree debris that has been historically sent to local landfills and disposal sites, creating an environmental burden and pressure on disposal sites around the nation. For more information about the company, visit www.TheSustainableGreenTeam.com.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, will host a conference call and webcast today at 1:30 p.m. PT (4:30 p.m. ET). The company scheduled the event to report results for its fiscal year 2023, the period ended March 31, 2023. The call will also include a corporate update. Those interested in participating on the call can dial 1-877-407-9716 (toll free in the United States) or 1-201-493-6779 (international callers), then use 13739679 as the conference ID number. A replay of the call will be available at approximately 5 p.m. (PT) today. Those interested in that replay may call toll free 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally (toll), then use the replay access ID number 13739679.

To listen to the full call, visit https://ibn.fm/pQREw

To view the full press release, visit https://ibn.fm/kifYn

About Vistagen Therapeutics Inc.

Vistagen Therapeutics is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company is advancing therapeutics with the potential to be faster acting and with fewer side effects and safety concerns than treatments that are currently available for treating anxiety, depression and multiple CNS disorders. Vistagen’s pipeline includes six product candidates, including fasedienol (“PH94B”), itruvone (“PH10”) and three additional investigational agents belonging to a new class of drugs known as pherines, in addition to AV-101, which is an oral antagonist of the N-methyl-D-aspartate receptor (“NMDAR”). Pherines, which are administered as nasal sprays, are designed with a novel rapid-onset mechanism of action that activates chemosensory neurons in the nasal passages and can beneficially impact key neural circuits in the brain without systemic uptake or direct activity on CNS neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety, depression and several other CNS disorders. For more information about the company, please visit www.Vistagen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN  

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Hillcrest (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA), an innovative clean technology company redefining power conversion technologies and advanced control system solutions, today provided a shareholder update on recent activities. Among the highlights, Hillcrest reiterated that it recently completed dynamic load bench demonstrations of its 800-volt (“V”), 250-kilowatt (“kW”) SiC traction inverter attended by a prominent European automotive original equipment manufacturer (European “OEM”). On the heels of completing analysis of the demonstration results, the European OEM is proceeding with the next phase of co-development. “Our technology continues to meet or exceed expectations in demonstrations,” said Hillcrest CEO Don Currie. “Having successfully demonstrated the technology’s capabilities to the European OEM and now moving to the next phase in the process is a testament to our team’s abilities and an important opportunity for collaboration. Their commitment provides further validation of our ZVS technology and moves us another step closer to a potential commercial transaction.”

To view the full press release, visit https://ibn.fm/xYxWL

About Hillcrest Energy Technologies Ltd.

Hillcrest is a clean technology company developing high-value, high-performance power conversion technologies and digital control systems for next-generation powertrains and grid-connected renewable energy systems. From concept to commercialization, Hillcrest is investing in the development of energy solutions that will power a more sustainable and electrified future. Hillcrest is publicly traded on the CSE under the symbol HEAT, on the OTCQB Venture Market as HLRTF and on the Frankfurt Exchange as 7HIA. For more information, please visit www.HillcrestEnergy.tech.

NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Amesite (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for education, business and government markets, today announced that V6.3 will be available to its customers on July 10, 2023. “We are thrilled to announce the roll out of our latest update – V6.3 – utilizing a streamlined, AI-first infrastructure. Our enterprise customers are in a phase of rapid expansion, and they need reliable solutions that support their growth,” said Amesite founder and CEO, Dr. Ann Marie Sastry. “Our AI-driven platform features can now be delivered with even greater scalability and affordability, along with greater degrees of customization, to meet our customers’ needs.”

To view the full press release, visit https://ibn.fm/7jppX

About Amesite Inc.

Amesite delivers its scalable, customizable, white-labeled online learning platform to universities, businesses, museums and government agencies, enabling them to deliver outstanding digital learning. Amesite provides a single system that combines eCommerce, instruction, engagement, analytics, and administration using best-in-class infrastructure to serve multibillion-dollar online learning markets. For more information, visit https://amesite.com.

NOTE TO INVESTORS: The latest news and updates relating to AMST are available in the company’s newsroom at https://ibn.fm/AMST

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Flora Growth (NASDAQ: FLGC), a consumer-packaged goods leader serving all 50 states with more than 15,000 points of distribution around the world and a pharmaceutical distributor in 28 countries, has named two new executive appointments. The company announced that Clifford Starke has been appointed as CEO and Dany Vaiman has been appointed CFO. Previously serving as president of Flora Growth, Starke is taking over the reins from Hussein Rakine, who resigned as CEO but will remain as a member of the board of directors; Starke is also a director for the company. Before joining Flora Growth, Starke served as the CEO and executive chair of Franchise Global Health Inc. and, for the past five years, he has also been chair at Hampstead Private Capital Ltd., a Bermuda-based merchant bank. Before becoming CFO, Vaiman served as Flora Growth’s senior VP of finance; he also comes from Franchise Global Health Inc., where he was CFO. He has been corporate controller of Torex Gold Resources Inc. and has impressive auditing and accounting experience with Ernst & Young. Starke’s appointment “comes at an opportune moment with the cannabis industry at a critical juncture,” the company stated in the press release. “Cannabis licensed producers have encountered significant policy issues, oversupply leading to price decreases, and capital constraints leading to overleveraged balance sheets. In the United States, the company believes potential for large-scale mergers is limited due to state specific restraints disallowing competition while the opportunity in the international market is robust, and Flora, with an already significant footprint, is positioned to emerge as a premier international company.

In the United States, Flora’s lifestyle business has established a presence across all 50 states, providing the company with a solid foundation. Furthermore, we believe we possess substantial potential for international expansion.”

The company also announced that it has received formal notification that it has regained compliance with minimum bid price requirement for the NASDAQ market exchange. The company is in compliance with all applicable listing standards and will continue to be listed and traded on the NASDAQ Stock Market.

To view the full press release, visit https://ibn.fm/yESHv

About Flora Growth Corp.

Flora Growth is a consumer-packaged goods leader serving all 50 states with 15,000-plus points of distribution around the world and is a pharmaceutical distributor in 28 countries. In the United States, Flora’s lifestyle business has established a robust presence across all 50 states, providing the company with a solid foundation. Furthermore, the company possesses substantial potential for international expansion. Based in Germany, Flora Growth has successfully developed a strong distribution network delivering lifestyle and wellness products to 28 countries. For more information about the company, please visit www.FloraGrowth.com.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

• FEXD is a company working to stay at the forefront of fintech innovations by using the most advanced financial technologies in its platforms and applications
• The company is seeking to acquire and merge with high-growth global fintech organizations that leverage these advanced financial technologies as part of its goal to develop a global fintech ecosystem
• Among these technologies are crypto and the blockchain
• Cryptocurrencies have been known to facilitate faster and lower-cost transactions, increase financial inclusions, and store value, especially in emerging economies where unpredictable inflation substantially weakens the value of their national currencies
• FEXD is committed to supporting the progress of developing countries and cultures, with cryptocurrencies playing a crucial role in helping the company achieve this goal

In a May 2022 report, rating agency Moody’s noted the highest cryptocurrency adoption was among lower-rated sovereigns. A summary of the report (https://ibn.fm/vUIRX) attributed this to the fact that digital currencies can facilitate “faster, more convenient, and lower-cost transactions for households and increase financial inclusion, benefitting countries where large parts of the population lack banking infrastructure.” Moreover, the summary continued, “improved access to cheaper and more reliable internet data, mobile phone usage, and, more broadly, the trend of increased digitization will also drive cryptocurrency adoption in many lower-income emerging markets.”

Moody’s assessment is part of the consensus of opinions around cryptocurrency. Experts and observers alike agree that global crypto adoption has been dominated by emerging markets, with lower-middle and upper-middle-income economies dominating the top 20 entries of the most recent…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FEXD are available in the company’s newsroom at https://ibn.fm/FEXD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

MetAlert (OTC: MLRT), a pioneer in location-sensitive, health-monitoring devices and wearable technology products for remote patient monitoring, has inked an agreement with HandsFree Health (“HFH”) to expand its service offerings. According to the agreement, MLRT will now be able to offer HFH’s Go Digital Health Tool to its customers; the HFH solution is a mobile health solution designed to support compliance and healthcare management. The app also includes access to a nationwide urgent care telehealth service. MetAlert announced that it will begin early enrollment for the service on July 1, 2023. Those using the app will be able to track key health indicators, including blood pressure, glucose, heart rate, temperature and weight; chart their progress; schedule appointments and reminders; and search for providers. The app also features the WellBe(R) HIPAA-compliant smart health assistant. The voice-enabled digital health platform uses AI to help connect users, caregivers, families, and even businesses to key health and wellness information.

“This is one more piece of MetAlert’s 360-degree approach to provide additional subscription services for comprehensive remote patient monitoring and long-term predictive analytics, to the ADA community we serve,” said MetAlert CEO Patrick Bertagna in the press release. “With our patented GPS SmartSole plus 3D infrared RoomMate for indoor remote-patient monitoring, and now adding telehealth urgent care and WellBe (your AI smart health assistant), MetAlert is able to provide a host of data collection wearable devices, wander assistance with real-time recovery, fall-prevention assistance, remote urgent-care assistance, and symptoms and treatment assistance, all under one platform, with easy monthly payments.”

To view the full press release, visit https://ibn.fm/DHjkL

About MetAlert Inc.

MetAlert and its subsidiaries are engaged in designing, developing, manufacturing, distributing, selling and licensing products, services and intellectual property in the GPS/BLE wearable technology, personal location, wandering assistive technology, and health data collection and monitoring. With more than 20 years of experience and an extensive patent portfolio, MetAlert is a leading solution provider for consumers/patients afflicted with Alzheimer’s, dementia and autism. This market represents approximately 2.9% of the world’s population. The company offers global end-to-end hardware, software and connectivity solutions, in addition to developing two-way tracking technologies, which seamlessly integrate with consumer products, enterprise and government agency applications. Utilizing the latest in miniaturized, low-power consumption GPS, cellular, RF, NFC and BLE technologies, enabling caregivers to track and monitor patients in real time. The company is known for its game-changing and award-winning patented GPS SmartSole(R) — think Dr. Scholl’s meets LoJack, the world’s first invisible wearable technology tracking device created for those at risk of wandering due to Alzheimer’s, dementia, autism and traumatic brain injury. MetAlert’s subscription-based business model is built around technology innovation with intellectual property protection. The company has international distributors servicing customers across the globe with subscribers in more than 40 countries and is a U.S. military government contractor. Other customers include public health authorities, municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes and consumers. For more information about this company, please visit www.MetAlert.com.

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Nemaura (NASDAQ: NMRD), a medical technology company focused on non-invasive wearable sensors and personalized weight reduction programs, today announced the next commercialization stage of its proBEAT(TM) sensor and AI-based feedback platform, augmenting the BEAT(TM) diabetes program. Intended as a precursor to revenue-generating contracts for proBEAT, the pilots will commence over the coming weeks and months. “The expansion of the BEAT diabetes program into employers and insurers in the U.S. represents significant progress towards bringing more innovative diabetes care solutions to our target markets,” said Nemaura’s CEO Dr. Faz Chowdhury. “Importantly to Nemaura, this is a big step toward revenue generation with our proBEAT platform, and we aim to continue the momentum over the coming months and years. We spent a vast amount of time and resources optimizing and scaling our sensor manufacturing processes and it’s extremely fulfilling for the team to see their hard work come to fruition through these developments, bringing cost-effective solutions to the market.”

To view the full press release, visit https://ibn.fm/bxPKL

About Nemaura Medical Inc.

Nemaura is a medical technology company developing and commercializing noninvasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE mark approved Class IIb medical device, is a noninvasive and flexible continuous glucose monitor (“CGM”) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT to the U.S. FDA. proBEAT combines noninvasive glucose data processed using artificial intelligence under a digital health care subscription service as part of its BEAT(R) diabetes program. The company sits at the intersection of the global type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information, visit www.NemauraMedical.com and www.BEATdiabetes.Life.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

RYVYL (NASDAQ: RVYL), a company that leverages the security of the blockchain and USD-pegged stablecoin technology with near-real-time attestation to conduct payment transactions, and its wholly-owned subsidiary in Europe, RYVYL EU, have partnered with Visa. The company announced that the strategic partnership allows RYVYL EU’s customers to use Visa Direct, a state-of-the-art, account-to-account transfer solution. According to the announcement, the two companies are working to “revolutionize the way funds are transferred between accounts, providing fast, convenient, and secure transactions.” The agreement enables RYVYL EU customers to access highly advanced and convenient payment services via Visa Direct, providing seamless and secure international transactions to authorized accounts in more than 80 countries without needing correspondent banks. The company noted that this service is especially beneficial in areas with low card usage but high bank account access, such as Asia Pacific and Latin America.

“We are excited that RYVYL EU has been selected as Visa’s first partner in Bulgaria for its Visa Direct solution due to our long-standing relationship as a principal member and our comprehensive range of payment solutions that align perfectly with Visa Direct account-to-account transfers,” said RYVYL CEO and cofounder Fredi Nisan in the press release. “This partnership is also one of the first few in the Eastern Europe region. Facilitating transfers through Visa Direct gives RYVYL EU a competitive advantage over other financial institutions allowing the services that the RYVYL family of companies provide to keep pace in the rapidly evolving payments industry. It aligns with the RYVYL’s strategic objectives, which include potential revenue growth, industry leadership in the money movement sector, expansion into new markets and customer bases, and delivering a best-in-class user experience.”

To view the full press release, visit https://ibn.fm/DMKIZ

About RYVYL

RYVYL was born from a passion for empowering a new way to conduct business-to-business, consumer-to-business and peer-to-peer payment transactions around the globe. By leveraging unique blockchain security and USD-pegged stablecoin technology with near real-time attestation, RYVYL is reinventing the future of financial transactions using its coyni(R) stablecoin platform as a transactional foundation. Since its founding as GreenBox POS in 2017, RYVYL has developed applications enabling an end-to-end suite of turnkey financial products with enhanced security and data privacy, world-class identity-theft protection and rapid speed to settlement. As a result, the platform can log immense volumes of immutable transactional records at the speed of the internet for first-tier partners, merchants and consumers around the globe. For more information about the company, please visit www.RYVYL.com.

NOTE TO INVESTORS: The latest news and updates relating to RVYL are available in the company’s newsroom at https://ibn.fm/RVYL

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Siyata Mobile (NASDAQ: SYTA, SYTAW), a global vendor of push-to-talk over cellular (“PoC”) devices and cellular signal booster systems, today announced the pricing of a public offering of 50,000,000 common shares, each at a price of $0.045. The company expects approximately $2.25 million in gross proceeds, prior to deducting placement agent fees, commissions and other offering expenses. Subject to customary conditions, the offering is expected to close on or about June 28, 2023. Maxim Group LLC is acting as the sole placement agent in connection with the offering.

To view the full press release, visit https://ibn.fm/w1gCl

About Siyata Mobile Inc.

Siyata Mobile is a B2B global vendor of next-generation push-to-talk over cellular devices, cellular booster systems and video monitoring solutions. Its portfolio of in-vehicle and rugged devices enables first responders and enterprise workers to instantly communicate, over a nationwide cellular network of choice, to increase situational awareness and save lives. Its portfolio of enterprise-grade and consumer cellular booster systems enables first responders and enterprise workers to amplify cellular signals in remote areas, inside structural buildings where signals are weak, and within vehicles for the maximum cellular signal strength possible. For its video monitoring system, Siyata integrates software that it licenses with off-the-shelf hardware providing its customers with an integrated advanced camera system for management and visual monitoring of their fleet vehicles. Siyata’s common shares and previously issued warrants trade on the Nasdaq under the symbols SYTA and SYTAW, respectively. For more information about the company, visit www.SiyataMobile.com and UnidenCellular.com.

NOTE TO INVESTORS: The latest news and updates relating to SYTA are available in the company’s newsroom at https://ibn.fm/SYTA          

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Pressure BioSciences (OTCQB: PBIO), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty-testing services to the worldwide pharmaceuticals, biotherapeutics, nutraceuticals, cosmeceuticals, agrochemical, food & beverage, cannabis, and other industries, has scheduled an online webinar today at 4:30 p.m. ET. The webinar will feature PBIO president and CEO Richard T. Schumacher, who will provide an overview of the company and its groundbreaking technologies and products. Titled “From Concepts to Success: Pressure BioSciences UltraShear(TM) Platform Revolutionizing Cannabis, Nutraceuticals, Cosmeceuticals, and Multiple Other Industries,” the webinar is designed to help attendees learn about the company’s powerful UltraShear Technology platform and gain and understanding of its potential transformative impact on various industries. The webinar, which will feature an interactive Q&A session, will also include insights into PBIO’s first-quarter 2023 record financial results and future prospects.

In addition, Pressure BioSciences is reporting on results from a third round of consumer focus-group testing of its THC Nanoemulsion Oral Spray; the spray, which uses the UltraShear technology, is designed for rapid, direct absorption through the cheeks and under the tongue. According to the report, 25 consumers participated in the testing, with results showing key attributes that powerfully differentiate UltraShear processed Nano-THC Oral Spray from edible THC experiences. Specifically, the results indicate speedy onset of first effects, faster progression to maximum effects, elimination of health issues associated with smoking or vaping and efficiency improvements in dose payload delivery. “These extended study results have confirmed the potential for a market transformation in THC consumption with a new oral/transdermal dosing modality in between the existing smoke/vape and edible food/beverage bifurcation of this enormous market,” said Pressure BioSciences president and CEO Richard T. Schumacher in the press release. “We believe that the customer experience with UltraShear processed Nano-THC will be compelling to drive a tidal change in the market, with potential for explosive adoption of UltraShear processed Nano-THC. We are experiencing similar reactions and developments as we work with early partners across multiple other markets in nutraceuticals, cosmeceuticals, food/beverage, and more. The second half of 2023 is poised to be a watershed transformational time for PBI, as we capitalize on the roll-out of the UltraShear platform, not just in cannabis, but across other major consumer-driven markets as well.”

To view the webinar, visit https://ibn.fm/xlz4n

To view the full press releases, visit https://ibn.fm/Ua8L8 and https://ibn.fm/mhdmX

About Pressure BioSciences Inc.

Pressure BioSciences is a global leader in providing innovative, broadly enabling, high-pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical and agrochemical, as well as food and beverage manufacturing. The company’s products utilize both constant and alternating pressure. Its patented enabling technology platform — Pressure Cycling Technology (“PCT”) — features alternating cycles of pressure to control biomolecular interactions, such as cell lysis and biomolecule extraction, safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counterbioterrorism applications. PBIO has recently expanded its market opportunities with the acquisition of the BaroFold(TM) patented technology platform, allowing the company to enter the biopharma contract services and GMP manufacturing equipment sector. The company has also developed the scalable and high-efficiency pressure-based UltraShear Technology platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room-temperature-stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. The company’s commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to its customers. For more information, visit the company website at www.PressureBioSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has appointed Sanford R. Climan as a strategic advisor. The CEO and founder of Entertainment Media Ventures Inc., Climan is an active venture investor who has also served as a board member and senior advisor to an impressive array of companies. Entertainment Media Ventures is a Los Angeles-based advisory and investment company specializing in identifying opportunities in healthcare, technology, and media & entertainment industries. Climan has also served in senior management positions at Universal Studios and Metro-Goldwyn-Mayer Studios (“MGM”) and its affiliated production companies. In addition, Climan was a key member of the senior-management team at Creative Artists Agency, where he worked on teams with several Fortune 500 Companies, including Sony Corporation on its acquisition of Columbia Pictures, Matsushita Electric on its acquisition of MCA/Universal, and Credit Lyonnais on its restructuring of MGM. “Mr. Climan’s impressive background and experience in financial and healthcare industries, particularly in innovative sectors, aligns with Cybin’s mission of developing new, differentiated therapeutics for mental health conditions,” said Cybin CEO Doug Drysdale in the press release. “We are pleased to have Mr. Climan’s expertise in shaping our strategic initiatives as we continue to advance our clinical-stage programs towards key data catalysts later this year, with the goal of bringing transformative therapies to people in need of improved treatment options.”

To view the full press release, visit https://ibn.fm/dQb0c

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder; the company also has a research pipeline of investigational psychedelic-based compounds. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence (“AI”) and machine-learning capabilities, its extensive biorepository of tumor samples, and its Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development, has appointed a new member to its business advisory board. The company announced that biopharmaceutical finance veteran Andrew Einhorn will be serving in the capacity. Cofounder and CFO of Oceana Therapeutics Inc., Esprit Pharma Inc. and ESP Pharma Inc., Einhorn brings an impressive wealth of experience to his new role. Nothing that the AI market for early drug discovery is growing rapidly and that POAI is uniquely positioned to be a leader in the emerging industry, Einhorn stated that he looks forward to helping the company achieve its full operational and financial potential. Einhorn currently works at Danforth Advisors providing financial advisory services to a range of public and privately held companies. He also has experience in investment banking and capital markets, managing debt, equity and structured financing transactions with institutional investors. “Andrew Einhorn brings a wealth of senior financial leadership experience in the biopharmaceutical industry to our Business Advisory Board, and I am very pleased that he has agreed to join,” said Predictive Oncology CEO Raymond F. Vennare in the press release. “As our momentum continues to accelerate, Andrew’s insights, expertise and perspectives will be invaluable in our persistent efforts to deliver unique solutions to our drug development partners while creating lasting value for our shareholders.”

To view the full press release, visit https://ibn.fm/xNI5K

About Predictive Oncology Inc.

Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence (“AI”) and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. With PEDAL and the company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based, drug-discovery solutions, further complimented by its wholly owned CLIA lab and GMP facilities. For more information about the company, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Nautilus (NYSE: NLS) recently announced its entry into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 4,098,362 shares of its common stock (or common stock equivalents), each at a purchase price of $1.22, in a registered direct offering. In addition, in a concurrent private placement, Nautilus announced that it would issue the investor warrants to purchase up to 4,098,362 shares of common stock. The warrants, with an exercise price of $1.35 per share, will have a 5 1/2-year term and be exercisable six months following the date of issuance. From gross proceeds of approximately $5 million, the company intends to use the net proceeds from the offering for general corporate purposes.

To view the full press release, visit https://ibn.fm/3pQtH

About Nautilus, Inc.

Nautilus is a global leader in digitally connected home fitness solutions. The company’s brand family includes Bowflex(R), Nautilus(R), Schwinn(R), and JRNY(R), its digital fitness platform. With a broad selection of exercise bikes, cardio equipment and strength-training products, Nautilus empowers healthier living through individualized connected fitness experiences and, in doing so, envisions building a healthier world, one person at a time. Headquartered in Vancouver, Washington, the company’s products are sold direct to consumer on brand websites and through retail partners and are available throughout the U.S. and internationally. For more information about the company, visit www.nautilusinc.com/investors.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

DarioHealth (NASDAQ: DRIO), a leader in the global digital health market, reported on a retrospective cohort study at the recent American Diabetes Association (“ABA”) 83rd Scientific Sessions. According to the announcement, the study analyzed real-world data of Dario users against matched controls, with results showing significant improvements in HbA1c for Dario users with serious diabetes. The Scientific Sessions were held June 23–26, 2023, in California. The announcement noted that, “in an industry first,” analysis found statistically significant reductions in HbA1c compared to matched controls across real-world user data. Further analysis revealed that when baseline HbA1c reflected more serious diabetes the difference was even greater. Specifically, the study reported a 2.3-point reduction in HbA1c for Dario digital health users with baseline HbA1c greater than 9 points. “There is a growing need to bring higher quality evidence generation in digital health,” said DarioHealth chief medical officer Omar Manejwala in the press release. “We believe that Sanofi’s new research ensures Dario is leapfrogging others in the space in terms of quality of evidence as well as clinical effect sizes. With payers rightly demanding rigor in evidence for digital health solutions, this new evidence ensures that Dario is uniquely positioned to exceed these requirements.”

To view the full press release, visit https://ibn.fm/00EcG

About DarioHealth Corp.

DarioHealth Corp. is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multichronic condition digital therapeutics platform. Dario’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. The company’s user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results, and making the right thing to do the easy thing to do. Dario provides its highly user-rated solutions globally to health plans and other payors, self-insured employers and providers of care as well as directly to consumers. For more information about the company, please visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Amesite (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets, today announced its receipt of an award from the National Association for Business Resources: Michigan’s Best & Brightest in Wellness(R) for the fifth consecutive year. “Maintaining a culture where our highest performers thrive has allowed us to increase our revenue, reduce operating costs significantly and launch best-in-class products,” said Amesite founder and CEO Dr. Ann Marie Sastry. “We know when we create a great environment, we attract great people and when we attract great people we maintain a great environment.”

To view the full press release, visit https://ibn.fm/9aGZt

About Amesite Inc.

Amesite delivers its scalable, customizable, white-labeled online learning platform to universities, businesses, museums and government agencies, enabling them to deliver outstanding digital learning. Amesite provides a single system that combines eCommerce, instruction, engagement, analytics, and administration using best-in-class infrastructure to serve multibillion-dollar online learning markets. For more information, visit https://amesite.com.

NOTE TO INVESTORS: The latest news and updates relating to AMST are available in the company’s newsroom at https://ibn.fm/AMST

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Eat Well Group (CSE: EWG) (OTC: EWGFF), a leading plant-based food ingredient and CPG company, has entered into a definitive membership interest purchase agreement (“MIPA”) as part of a NASDAQ merger with TRxADE Health Inc. (NASDAQ: MEDS). The MIPA outlines the sale of Sapientia Technology Inc., EWGFF wholly-owned subsidiary, to Superlatus Inc. According to the Eat Well, the move is part of its commitment to sharpening its focus and leveraging its global agricultural strategy by divesting noncore assets. The sale of Sapientia, which will be for $10 million, “unlocks significant value and positions the company for exponential growth in collaboration with MEDS and Superlatus Foods,” the announcement noted. In addition, the announcement indicated that Superlatus is completing a merger with TRxADE on the NASDAQ exchange, which calls for Superlatus shareholders to receive more than 30 million shares of MEDS. Following the merger, TRxADE will focus on becoming an industry-leading processing and forming technologies company; the company plans to offer high-nutrition, texture plant-based foods and snacks. The announcement stated that TRxADE will divest its existing operating business and assets shortly after the merger. “We are very pleased to announce the sale of Sapientia for USD $10 million, allowing us to unlock the value of our IP portfolio and retain a substantial position in the NASDAQ company, MEDS,” said Eat Well Group CEO Marc Aneed in the press release. “This strategic move allows us to double down on our agricultural strategy and pursue further M&A opportunities, which will help establish Eat Well as a leading global agricultural platform.”

To view the full press release, visit https://ibn.fm/Yn9LE

About Eat Well Investment Group Inc.

Eat Well Group is a pioneering Canadian-based company leading the way in the future of sustainable, plant-based foods. With a rich history spanning nearly 45 years, the company’s subsidiaries have been at the forefront of processing, distributing and marketing premium-quality plant-based foods. Operating with IP-driven facilities across North America, Eat Well distributes to more than 35 countries worldwide. With a talented team of some 80 employees, the company takes pride in its products consistently ranking among the top 10 globally. With its family of private label and owned brands, including Sapientia, Amara Organic Foods, Belle Pulses and Eat Well, the company is dedicated to feeding families worldwide with excellence and innovation. For more information about the company, please visit www.EatWellGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to EWGFF are available in the company’s newsroom at https://ibn.fm/EWGFF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

• FEXD’s aggressive expansion plan not only lines up with its core mission but is also a step toward carving out a significant market share in the global fintech market, which is projected to hit $500 billion in valuation by 2028
• The company is exploring blockchain technology, banking on how easier access to mobile phones has helped make money transfers more accessible
• FEXD is also optimistic that the technology it will not only cut down on the cost of transactions but also significantly grow its annual revenues
• Its management is confident in this approach, citing that the investments so far will give the company a “solid competitive position”

Fintech Ecosystem Development (NASDAQ: FEXD), a special purpose acquisition company (“SPAC”), is constantly exploring new ways to grow and improve the financial sector, specifically in line with creating and growing a global financial services ecosystem that addresses unmet mobile needs. Its focus has been on industrialized and developed countries and markets, all built on the understanding that digital money is fast replacing physical cash.

To this effect, FEXD has embarked on an aggressive acquisition plan that has seen the announcement of definitive agreements for business combinations with companies such as Rana Financial Inc., a Georgia corporation, and Mobitech International LLC, a limited liability company organized in the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FEXD are available in the company’s newsroom at https://ibn.fm/FEXD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

TRxADE Health (NASDAQ: MEDS), a pharmaceutical exchange platform provider, has entered a binding letter of intent (the “LOI”) to acquire Superlatus Inc., a U.S.-based holding company of food products and distribution capabilities (the “merger”). Upon closing of the merger, Superlatus shareholders will receive 30,821,918 shares of MEDS, each valued at $7.30, and comprised of (i) common shares in an amount representing 19.99% of the total issued and outstanding stock of MEDS after closing, and (ii) the remainder in shares of a new class of MEDS non-voting preferred stock, in each case multiplied by such shareholder’s pro rata percentage ownership. The merger is subject to customary closing conditions including completion of due diligence, delivery of audited financials, approval of a continued listing by Nasdaq and completion of any regulatory approvals.

Upon completion of the merger, TRxADE will pivot its business focus and branding to become an industry-leading processing and forming technologies company that creates the latest generation of delicious, high nutrition, high taste and texture plant-based foods and snacks. “This announcement is a significant milestone for TRxADE shareholders, and we believe that the combined entities will unlock significant value and synergies to be a significant player in the competitive food and snack marketplace,” said Suren Ajjarapu, founder, chairmen/CEO and director of TRxADE. “We believe this strategic transaction that restructures the business to focus on the combined strengths of each organization will provide a competitive advantage in the industry and allow us to gain market share through quality products, customer adoption, and through accretive acquisitions that will create substantial value and returns to our shareholders.”

To view the full press release, visit https://ibn.fm/zn70r

About TRxADE Health Inc.

TRxADE Health is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. The company operates the TRxADE drug procurement marketplace serving a total of 14,500+ members nationwide, fostering price transparency and, under the Bonum Health brand, offering patient-centric telehealth services. For more information on TRxADE Health, visit the company’s IR website at investors.trxadegroup.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has announced its June 22, 2023, receipt of a letter from the listing qualifications staff of the Nasdaq Stock Market LLC. The letter indicates that Vistagen has regained full compliance with the minimum $1.00 bid price per share or greater requirement under Nasdaq Listing Rule 5550(a)(2). Vistagen is now in full compliance with all applicable Nasdaq listing requirements, and Nasdaq considers the matter closed.

To view the full press release, visit https://ibn.fm/IKK8V

About VistaGen Therapeutics Inc.

Vistagen is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company is advancing therapeutics with the potential to be faster-acting and with fewer side effects and safety concerns than those that are currently available for treatment of anxiety, depression and multiple CNS disorders. Vistagen’s pipeline includes six clinical-stage product candidates, including five investigational agents belonging to a new class of drugs known as pherines and an oral prodrug of 7-Cl-CYNA, which is a full antagonist of the glycine site of the N-methyl-D-aspartate receptor (“NMDAR”). Pherines, which are administered as nasal sprays, are designed with an innovative rapid-onset mechanism of action that activates chemosensory neurons in the nasal passages and selectively impact key neural circuits in the brain without requiring systemic uptake or direct activity on CNS neurons. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety, depression and several other CNS disorders. For more information, visit the company’s website at www.Vistagen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) (FSE: 6BC0), a leading plant-based food ingredient and CPG company, today announced that it will prioritize its global agribusiness in order to drive debt reduction, improve profitability and long-term success. The company plans to achieve this through a number of moves that include closing the refinancing initiative, led by the Business Development Bank of Canada, maintaining a 28% ownership stake in PataFoods, Inc. dba Amara Organic Foods, resulting in a reduction of current liabilities by $7.05 million, prioritizing Belle Pulses, Eat Well’s wholly owned and profitable subsidiary, and seeking M&A opportunities in Fractionation, Pulse Processing and global agribusiness. In addition, the company intends to utilize available cash on the balance sheet to invest in Belle Pulses’ Canadian and U.S. operations to optimize efficiency and drive profitability across its three facilities.

To view the full press release, visit https://ibn.fm/oOP6s

About Eat Well Investment Group Inc.

Eat Well is a pioneering Canadian-based company leading the way in the future of sustainable, plant-based foods. With a rich history spanning nearly 45 years, its subsidiaries have been at the forefront of processing, distributing and marketing premium-quality plant-based foods. Operating with IP-driven facilities across North America, Eat Well distributes to over 35 countries worldwide. With a talented team of over 80 employees, the company takes pride in its products consistently ranking among the top 10 globally. With its family of private label and owned brands, including Sapientia, Amara Organic Foods, Belle Pulses, and Eat Well, the company is dedicated to feeding families worldwide with excellence and innovation. To learn more, join Eat Well’s mailing list for important updates.

NOTE TO INVESTORS: The latest news and updates relating to EWGFF are available in the company’s newsroom at https://ibn.fm/EWGFF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Exro Technologies (TSX: EXRO) (OTCQB: EXROF), a leading clean-technology company that develops new generation power-control electronics that expand the capabilities of electric motors and batteries, today provided a corporate. Among the highlights, the company provided details on the filing of two new U.S. provisional patent applications, upcoming interest payments per the terms of the C$15 million bought deal convertible debenture financing, and operational updates pertaining to both the evolution of its Traktionssysteme Austria (“TSA”) partnership and its on-track Coil Driver(TM) and Cell Driver(TM) series production scheduling. “Exro is thrilled to add two new U.S. provisional applications to its comprehensive intellectual property protection program, which includes over 40 patents published and pending and IP wholly owned in 14 patent families providing or seeking global protection in strategic countries,” said Exro CEO Sue Ozdemir. “These new technologies are not only examples of Exro’s commitment to research and innovation, but also promises of the multifold applications our technology and IP present in powertrains across the e-mobility and energy sectors.”

To view the full press release, visit https://ibn.fm/f9jqu

About Exro Technologies Inc.

Exro Technologies is a leading clean technology company that has developed new generation power control electronics that change how the world optimizes energy by expanding the capabilities of electric motors and batteries. The company’s innovative technologies serve to bridge the performance-cost gap in e-mobility (Coil Driver(TM)) and stationary energy storage (Cell Driver(TM)), and act to accelerate adoption towards a circular electrified economy by delivering more with less – minimum energy for maximum results. For more information visit the company’s website at www.Exro.com.

NOTE TO INVESTORS: The latest news and updates relating to EXROF are available in the company’s newsroom at http://ibn.fm/EXROF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Aura FAT Projects Acquisition Corp (NASDAQ: AFAR, AFARW), a publicly traded special purpose acquisition company, and Allrites Holdings Pte. Ltd., a leading global B2B content marketplace with cutting-edge proprietary content-as-a-service (“CaaS”) technology, recently announced the filing of a registration statement on Form F-4, which contains a preliminary proxy statement/prospectus, with the U.S. Securities and Exchange Commission (“SEC”) in connection with their recently proposed business combination. While the registration statement is not yet effective and subject to change, it provides important information about Allrites’ business and operations, the proposed business combination with AFAR, as well as the proposals to be considered by AFAR’s shareholders. On May 8, 2023, AFAR entered into a definitive Business Combination Agreement with Allrites, which is expected to close in the second half of 2023, subject to approval by AFAR shareholders, the registration statement being declared effective by the SEC, and other customary conditions. The transaction values Allrites at an estimated proforma enterprise value of $92.0 million.

To view the full press release, visit https://ibn.fm/kK4L1

About Aura Fat Projects Acquisition Corp.

AFAR is a blank check company listed on the Nasdaq formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. In April 2022, AFAR consummated a $115 million initial public offering. EF Hutton, division of Benchmark Investments LLC, served as the sole book-running manager of AFAR’s initial public offering. For more information, visit www.AuraFatProjects.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Golf is about doing something you like, with people you like – what a concept.

It’s hard to blame players and golf lovers from feeling blindsided by the announcement of a full-blown merger between two of golf’s major tours. The unexpected agreement between PGA Tour commissioner Jay Monahan and Saudi businessman Yasir bin Othman Al-Rumayyan, governor of the Saudi Public Investment Fund (“PIF”), that the PGA and LIV Golf would suddenly merge, was out-of-the-blue. After months of increasingly rancorous suits and court battles, “merger” wasn’t a term seen on a lot of radar screens.  

The PGA Tour, hosting tournaments in North America, and the DP World Tour, representing tournaments in Europe, had over time cooperated to build the world’s senior golf tours.  But when Golf Saudi (part of the Saudi Public Investment Fund, PIF) decided to fund a new “Super Golf League”, later launched as…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to GolfLync are available in the company’s newsroom at https://ibn.fm/GOLF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]